Abstract：
In 2012, the number of people infected with human T cell lymphotropic virus type 1 (HTLV-1) was estimated to be 10 million worldwide. Prevalence varies according to geographic location, ethnic factors, sex, age, populations exposed to risk factors, income, and education, reaching countries with the worst socioeconomic scenarios. There is a need to determine the current global prevalence of HTLV-1 and examine its association with countries\' human development index (HDI) to provide data for global health policy. Systematic review with meta-analysis is according to PRISMA 2020 recommendations. It was registered at PROSPERO, CRD42021223146. Prevalence or cross-sectional studies of HTLV-1 infection with at least 100 participants, screening, and confirmatory serologic testing were included. Studies with incomplete or unavailable results or with duplicate information were excluded. Data were selected by two independent investigators and analyzed using R software, a metapackage that generated the forest plots [95% confidence interval (CI)]. Heterogeneity was assessed using the I2 statistic, and funnel plot asymmetry was assessed using Egger\'s test. Countries were compared using an HDI cutoff ≥0.8. Methodological quality was assessed using Joanna Briggs Institute (JBI) criteria. The overall prevalence of HTLV-1 infection was 0.91% (95% CI: 0.80-1.02, p < .0001) and was higher in low HDI countries [1.18% (95% CI: 1.03-1.34)] than in high HDI countries [0.41% (95% CI: 0.27-0.57)]. Prevalence varied according to the populations studied: it was higher in the general population [1.65% (95% CI: 1.08-2.34)] compared to pregnant women [0.34% (95% CI: 0.17-0.57)] and blood donors [0.04% (95% CI: 0.01-0.08)]. Consistently, prevalence for each population group was higher in low HDI countries than in high HDI countries. The worldwide prevalence of HTLV-1 infection is highly heterogeneous, with a global prevalence of 0.91%. In high HDI countries, the observed prevalence is approximately three times lower than in low HDI countries. In the general population, the observed prevalence is about 5 times higher than in pregnant women and 41 times higher than in blood donors.
摘要：
背景技术2012年,全世界感染HTLV-1的人数估计为1千万。患病率因地理位置而异，民族因素,性别,年龄,暴露于危险因素的人群，收入,和教育，到达社会经济情景最差的国家。有必要确定HTLV-1的当前全球流行率，并检查其与各国人类发展指数（HDI）的关系，为全球卫生政策提供数据。方法根据PRISMA2020建议进行系统评价和荟萃分析。它在PROSPERO注册,CRD42021223146。至少有100名参与者的HTLV-1感染的患病率或横断面研究，筛选,并包括确认血清学检测。排除具有不完整或不可用结果或具有重复信息的研究。数据由两名独立的研究者选择，并使用R软件进行分析。产生森林地块的元包装(95%CI)。使用I²统计量评估异质性，漏斗图的不对称性使用Egger检验进行评估。使用HDI临界值≥0.8对各国进行比较。使用JoannaBriggs研究所标准评估方法学质量。结果HTLV-1感染的总体患病率为0.91%(95CI:0.80-1.02,p<0.0001)，低HDI国家[1.18%(95CI:1.03-1.34)]高于高HDI国家[0.41%(95CI:0.27-0.57)]。患病率根据所研究的人群而有所不同：普通人群[1.65％（95CI：1.08-2.34）]高于孕妇[0.34％（95CI：0.17-0.57）]和献血者[0.04％（95CI：0.01-0.08）]。始终如一，在低HDI国家,每个人群组的患病率高于高HDI国家.结论HTLV-1感染在世界范围内具有高度异质性,全球患病率为0.91%。在人类发展指数高的国家，观察到的患病率比低人类发展指数国家低大约3倍.在一般人群中,观察到的患病率是孕妇的5倍，是献血者的41倍。
